Welcome to our dedicated page for Lemaitre Vasculr SEC filings (Ticker: LMAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LeMaitre Vascular, Inc. filings document a Nasdaq-listed medical device company focused on vascular devices, implants, and services for peripheral vascular disease. Recent Form 8-K reports furnish quarterly operating and financial results, dividend-related updates, and related press release exhibits.
Proxy and governance filings cover board structure, director elections, executive compensation, advisory say-on-pay matters, and shareholder voting results. The filings also identify the company’s common stock, par value, Nasdaq Global Market listing under LMAT, and related public-company disclosure controls.
LeMaitre Vascular director Lawrence J. Jasinski reported grants of dividend equivalent rights on existing equity awards. On 2026-06-04, he acquired several small blocks of dividend equivalent rights linked to previously granted restricted stock unit and performance share unit awards from 2023, 2024, and 2025.
Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and will vest proportionately with the underlying awards. These are compensation-related accruals with no open-market buying or selling and no cash exercise price.
LeMaitre Vascular director John James O’Connor reported routine compensation-related grants of dividend equivalent rights. On June 4, 2026, he acquired several small awards of dividend equivalent rights tied to existing restricted stock unit and performance share unit awards granted on December 8, 2023, December 6, 2024, and December 10, 2025. Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and carries a stated price of $0.00 per right. Following these transactions, O’Connor directly holds 5.0674 dividend equivalent rights in total, which vest proportionately with the underlying stock and performance awards rather than representing open-market purchases or sales.
Roush John A reported acquisition or exercise transactions in this Form 4 filing.
LeMaitre Vascular director John A. Roush reported routine compensation-related transactions in the form of dividend equivalent rights on June 4, 2026. Five separate grants of dividend equivalent rights were credited in fractional amounts, each tied to existing restricted stock unit and performance share unit awards granted in December 2023, 2024, and 2025. Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and vests in step with the underlying equity awards. These awards involve no cash paid by Roush and do not reflect any open-market purchases or sales of shares.
LEMAITRE VASCULAR INC director Martha Shadan reported compensation-related awards of dividend equivalent rights tied to prior equity grants. On 2026-06-04, she acquired five derivative positions labeled as Dividend Equivalent Rights, each economically equivalent to one share of common stock and carrying no exercise price.
The rights accrued on restricted stock unit and performance share unit awards originally granted on 12/8/2023, 12/6/2024, and 12/10/2025, and will vest proportionately with those underlying awards. No open-market purchases or sales were reported, and all transactions were classified as grants or awards.
LeMaitre Vascular director Joseph P. Pellegrino Jr. reported several compensation-related grants of Dividend Equivalent Rights tied to existing equity awards. On June 4, 2026, he acquired small fractional rights on multiple restricted stock unit and performance share unit awards from prior grant dates.
Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and vests proportionately with the underlying award. The transactions are coded as awards (not open‑market trades), so they reflect routine accrual of additional rights rather than buying or selling shares in the market.
LeBlanc Dorian Paul reported acquisition or exercise transactions in this Form 4 filing.
LeMaitre Vascular’s Chief Financial Officer, Dorian Paul LeBlanc, received additional equity-linked compensation. On June 4, 2026, he was granted 3.1523 dividend equivalent rights tied to a restricted stock unit award granted on March 10, 2025, bringing his holdings in those rights to 5.8193. He also received 2.4759 dividend equivalent rights tied to a separate restricted stock unit award granted on December 10, 2025, increasing those holdings to 13.8976 dividend equivalent rights. Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and will vest proportionately with the related restricted stock unit awards.
LEMAITRE VASCULAR INC President and Director David B. Roberts reported routine compensation-related transactions involving dividend equivalent rights on June 4, 2026. These are derivative awards that mirror dividends on previously granted stock-based awards rather than open-market trades.
The filing shows nine acquisitions coded as grants, each adding small fractional dividend equivalent rights tied to restricted stock unit and performance share unit awards granted on December 12, 2022, December 8, 2023, December 6, 2024, February 18, 2025, and December 10, 2025. Each dividend equivalent right is the economic equivalent of one share of common stock and vests proportionately with its underlying award. No shares were bought or sold in the market.
Kamke Trent G reported acquisition or exercise transactions in this Form 4 filing.
LeMaitre Vascular Inc. senior vice president of operations Trent G. Kamke reported multiple small awards of dividend equivalent rights on Dividend Equivalent Rights instruments. All seven transactions on June 4, 2026 are coded as grants or awards, reflecting compensation-related accruals rather than market purchases or sales.
Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and accrued on previously granted restricted stock unit and performance share unit awards from December 2022, December 2023, December 2024, and December 2025. The rights vest proportionately with the underlying equity awards, and there were no open-market buys or sells disclosed in this filing.
LEMAITRE VASCULAR INC Chairman and CEO George W. LeMaitre reported a mix of estate-planning and compensation-related equity movements in company securities. He made a bona fide gift of 11,974 shares of common stock, after which his direct holdings stood at 1,418,045 common shares. A related irrevocable life insurance trust for the benefit of his children holds 45,374 common shares, and he disclaims beneficial ownership except for any pecuniary interest. In addition, he received several small grants of dividend equivalent rights tied to prior restricted stock unit and performance share unit awards, each economically equivalent to one share of common stock and vesting proportionately with the underlying awards.
LeMaitre Vascular, Inc. reported the results of its 2026 Annual Meeting of Stockholders. A total of 22,847,798 shares were entitled to vote as of April 6, 2026, and 21,336,301 shares were represented in person or by proxy.
Stockholders elected two Class II directors to three-year terms: David B. Roberts received 18,888,412 votes for and 1,250,012 withheld, while John A. Roush received 14,229,071 votes for and 5,909,353 withheld. An advisory vote approved executive compensation with 19,311,813 votes for and 813,052 against. Stockholders also ratified Grant Thornton LLP as independent registered public accounting firm for 2026 with 21,220,412 votes for and 108,474 against.